<DOC>
	<DOCNO>NCT02800811</DOCNO>
	<brief_summary>First-in-human , phase I , randomize , double-blind , placebo-controlled , single center study evaluate single multiple ascend intravenous dos FR104 healthy subject .</brief_summary>
	<brief_title>Safety , Tolerability , PK , PD , Immunogenicity Single Multiple Ascending Intravenous Doses FR104</brief_title>
	<detailed_description>This study first-in-human , phase I , randomize , double-blind , placebo-controlled , single center study evaluate single multiple ascend intravenous dos FR104 healthy subject . 64 healthy male female subject select accord inclusion exclusion criterion , i.e. , 50 subject Part 1 ( SAD : 2 cohort 22 [ Cohort A ] , 28 [ Cohort B ] , respectively ) 14 subject Part 2 ( MAD ) . The total duration study 10 month . All FR104 dos administer intravenously slow infusion least 30 minute . A staggered approach observe within dose level . An interval least 14 day ( last first administration ) observe dose level . Individual subject day dose dose least 60 minute apart .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subjects meet follow criterion eligible participate study : 1 . Male female , age 18 60 year , extremes include ; 2 . In good health condition [ medically stable ] determine basis medical history , vital sign , clinical laboratory testing , general physical examination perform screening ; Note : retest do case range clinical laboratory test value determine subject 's eligibility . This retest preferably do unscheduled visit . The result retest consider subject eligibility . If retest outside normal reference range , subject eligible inclusion investigator judge abnormality clinically significant . 3 . Electrocardiogram ( ECG ) within normal range , show clinically relevant deviation , judge investigator ; Note : retest do case range ECG value determine subject 's eligibility . 4 . Weighs least 50 kg 100 kg Body Mass Index ( BMI ) within normal range : 18.0≤BMI &lt; 30.0 kg/m2 ; 5 . Negative urine test select drug abuse screening ; 6 . Negative alcohol breath test screening ; 7 . Female subject postmenopausal surgically sterile ( hysterectomy , bilateral oophorectomy , tubal ligation ) ; 8 . Female subject negative pregnancy test screening ; 9 . Nonvasectomized male subject female partner childbearing potential must agree use effective method contraception 90 day last administration study drug ; 10 . Male subject agree donate sperm 90 day last administration study drug ; 11 . Willing adhere prohibition restriction specify protocol ; 12 . Informed Consent Form ( ICF ) sign voluntarily studyrelated procedure perform , indicate subject understands purpose procedure require study willing participate study ; 13 . Subjects EBVpositive per positive IgG EpsteinBarr nuclear antigen ( EBNA ) test ; 14 . Nonsmoker light smoker , i.e. , smoke maximal 5 cigarette ( 3 cigar 3 pipefull ) per day , ability willingness refrain smoking confinement ambulant visit clinical research center . For Part 1 , Cohort B : 15 . The subject undergo KLH challenge . Subjects meet one follow criterion exclude participation study : 1 . A history clinically significant ( determined investigator ) cardiac , endocrinology , hematology , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy exclude nonmelanoma skin cancer ; 2 . A known allergy , hypersensitivity , intolerance study drug , compound ; 3 . The subject history severe allergic anaphylactic reaction ; 4 . The subject history consume 21 ( 14 female ) unit alcoholic beverage per week history alcoholism drug/chemical/substance abuse within past 2 year prior screen ( Note : one unit = 330 mL beer , 110 mL wine 28 mL spirit ) ; 5 . Evidence history clinically significant infection within past 3 month ; 6 . History evidence active latent inadequately treated infection Mycobacterium tuberculosis ( TB ) diagnose positive QuantiFERON® TBGold In Tube test positive tuberculin skin test ( `` Mantoux '' ) case weak positive QuantiFERON® TBGold In Tube test ; 7 . Subjects know clinically relevant immunological disorder , auto‑immune disorder , ( e.g. , rheumatoid arthritis , lupus erythematosus , scleroderma , etc ... ) ; 8 . Subjects recent infection EBV diagnose positive IgM VCA ; 9 . A positive hepatitis panel ( include hepatitis B surface antigen [ HBsAg ] antihepatitis C virus [ HCV ] antibodies [ Abs ] ) positive human immunodeficiency virus ( HIV ) antibody screen ; 10 . The subject supine systolic blood pressure ( SBP ) &lt; 90 &gt; 160 mmHg diastolic blood pressure ( DBP ) &lt; 50 &gt; 90 mmHg , pulse rate high 100 bpm , either screen ( blood pressure measurement take subject rest supine position minimum 5 minute ) ; Note : retest do case range vital sign value determine subject 's eligibility . The result retest consider subject eligibility . 11 . The subject pregnant breastfeeding ; 12 . The subject received vaccine within 60 day prior study drug administration ; 13 . The subject receive systemic immunosuppressant agent within 6 month prior study drug administration ; 14 . The subject receive antibody biologic medicinal product within 6 month prior study drug administration ; 15 . The subject receive systemic steroid within 2 month prior study drug administration ; 16 . Use prohibit therapy within 14 day prior study drug administration ; 17 . Receipt investigational drug within 30 day ten halflives , whichever longer , prior initial study drug administration ; 18 . The subject participate another clinical trial participate another dose group current trial ; 19 . Had significant blood loss ( include blood donation [ &gt; 500 mL ] ) transfusion blood product within 60 day donate plasma within 7 day prior initial study drug administration ; 20 . A condition , opinion investigator , could compromise well‑being subject course study , prevent subject meeting performing study requirement . 21 . Intent visit region tuberculosis mycosis endemic period 3 month dose ( 4 month dose subject Cohort C ) , i.e. , desert area , Eastern Europe , Central South America , Africa except Egypt , Russia , Asia , Indonesia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>FR104</keyword>
	<keyword>CD28</keyword>
	<keyword>immunomodulation</keyword>
	<keyword>T regulatory cell</keyword>
	<keyword>Pegylated monovalent anti-CD28 Fab antibody</keyword>
</DOC>